SIRPA and neoplasm: For instance, Ring et al. [226] showed that the anti-SIRPα antibody KWAR23 in combination with tumor-opsonizing monoclonal antibodies greatly augmented the myeloid cell-dependent killing of human tumor-derived cell lines in vitro and in vivo.